Atavistik Bio is a biotechnology company focused on discovering and developing small molecule therapies that target allosteric sites on proteins to treat metabolic diseases and cancer. They leverage their proprietary platform to identify novel binding sites and create highly specific drugs. Founded in 2020, Atavistik Bio aims to revolutionize treatment paradigms by addressing previously undruggable targets, thereby creating new therapeutic options and revenue streams through innovative drug development.